Ref: JSTL/BOD/BSE/2024-25/Feb25 **Date: February 06, 2025**

To,
The Manager
BSE Limited
P. J. Towers, Dalal Street
Mumbai-400001

Dear Sir/ Madam,

Sub: Outcome of Board Meeting held on 06.02.2025

Unit: Jeevan Scientific Technology Limited (Scrip Code: 538837)

With reference to the subject cited, this is to inform the exchange that the Board of Directors of Jeevan Scientific Technology Limited at its meeting held on Thursday 06.02.2025 at 03:30 p.m. at the registered office of the Company, inter alia approved the following items of business:

1. Un-audited Financial Results (Standalone and Consolidated) for the Quarter and Nine Months ended 31st December 2024. (Enclosed as **Annexure I**).

2. Limited Review Report (Standalone and Consolidated) for the Quarter ended 31st December 2024. (Enclosed as **Annexure II**).

3. Appointment of Mr. Venkateswara Rao Ravipati as Chief Financial Officer of the Company w.e.f. 06.02.2025. **(Brief Profile attached as Annexure III)**

4. Investment of Rs. 24.00 Crores in M/s. Naya Pharma Private Limited, subject to the approval of Shareholders. Both the companies (Investing and Investee Companies) have the common promoters and the directors and hence amounts to related party transaction. **(Enclosed relevant disclosures as Annexure IV).**

5. To provide Loan and / or Corporate Guarantee to M/s. Naya Pharma Private Limited - Material Related party transaction. **(Enclosed relevant disclosures as Annexure V).**

6. Mr. Krishna Kishore Kuchipudi, Managing Director of the Company is authorized to fix the date, time and venue of the Extra Ordinary General Meeting of the Company to invest in, provide loan and / or corporate guarantee to M/s. Naya Pharma Private Limited.

The meeting concluded at 06:45 P.M.

This is for the information and records of the Exchange, please.

Thanking You.

Yours faithfully,
For Jeevan Scientific Technology Limited

Kuchipudi Krishna Kishore
Digitally signed by Kuchipudi Krishna Kishore
Date: 2025.02.06 19:01:30 +05'30'

Krishna Kishore Kuchipudi
Vice Chairman and Managing Director
(DIN: 00876539)

Encl as above

Annexure III

[Details under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with clause 7 of Para A of Annexure I of SEBI Circular dated July 13, 2023]

Reason for change viz. appointment, resignation, removal, death or otherwise	Appointment of Mr. Venkateswara Rao Ravipati as Chief Financial Officer of the Company.
Date of appointment & Terms of appointment	w.e.f. 06.02.2025.
Brief Profile	Mr. Venkateswara Rao Ravipati has 20+ years of experience in Accounts, Tax and Finance function. Mr. Venkateswara Rao Ravipati is a Commerce Post Graduate with 20+ years of extensive experience in finance, GST laws, Income Tax Laws, Budget Preparation, Finalization of Quarterly and Annual Accounts, Preparation of financials for Internal & Statutory Audits, Timely preparation of all Monthly, Quarterly and Annual accounts, Books of accounts maintained as per various Accounting Standards and Company policies from time to time.
Disclosure of relationships between directors (in case of appointment of a director)	None

Annexure IV

[Details under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with clause 7 of Para A of Annexure I of SEBI Circular dated July 13, 2023]

S. No.	Particulars	Details
1.	Name of the target entity, details in brief such as size, turnover etc.;	M/s. Naya Pharma Private Limited
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length";	Yes. • Mrs. Snigdha Mothukuri and Mrs. K. Vanaja are the shareholders of the Company for 100% shareholding. • As on date the Company has three directors held by Mr. K. Krishna Kishore, Mrs. Snigdha Mothukuri and Mrs. K. Vanaja. The above said two shareholders are also promoters of the investing Company (Jeevan Scientific Technology Limited). Mr. K. Krishna Kishore and Mrs. Snigdha Mothukuri are Common Directors on the Boards of both the investing and investee companies.
3.	Industry to which the entity being acquired belongs;	Pharma Sector
4.	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	As part of diversification and expansion of the existing business, the Company intends to acquire the companies engaged in pharma sector which also creates synergy for the clinical trials business undertaken by the Company.
5.	Brief details of any governmental or regulatory approvals required for the acquisition;	NIL
6.	Indicative time period for completion of the acquisition;	Acquisition will be completed in different trenches from time to time.

7.	Consideration - whether cash consideration or share swap or any other form and details of the same;	Cash
8.	Cost of acquisition and/or the price at which the shares are acquired;	Rs. 24.00 Crores
9.	Percentage of shareholding / control acquired and / or number of shares acquired;	60 % on the post issue paid capital of M/s. Naya Pharma Private Limited.
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	M/s. Naya Pharma Private Limited was incorporated on 19/08/2020 and current paid-up capital is Rs. 2,46,42,450 divided into 24,64,245 equity shares Rs. 10/- each. The objects of the Company include Manufacture, producers, buyers, sellers, importers, exporters, traders, dealers, wholesalers and retailers in Active Pharmaceutical Ingredients (bulk drugs), Drug Intermediates, Organic & In Organic chemicals, Fine Chemicals, Dye Pigments in India and /or abroad.

Annexure V

[Details under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with clause 7 of Para A of Annexure I of SEBI Circular dated July 13, 2023]

Sl. No	Particulars	Description
1	Name of party for which such guarantees or indemnity or surety was given	M/s. Naya Pharma Private Limited
2	whether the promoter/ promoter group/ group companies have any interest in this transaction? If yes, nature of interest and details thereof and whether the same is done at "arms length"	Yes. • Mrs. Snigdha Mothukuri and Mrs. K. Vanaja are the shareholders of the Company for 100% shareholding and the same is done at arm's length.
3	Brief details of such guarantee or indemnity or becoming a surety viz. brief details of agreement entered (if any) including significant terms and conditions, including amount of guarantee	Jeevan Scientific Technology Limited would provide Loan and / or Corporate Guarantee to M/s. Naya Pharma Private Limited for an aggregate value up to Rs. 90,00,00,000 (Rupees ninety crores only) and interest there on from time to time.
4	Impact of such guarantees or indemnity or surety on listed entity.	M/s. Naya Pharma Private Limited will be setting up State of Art, Research and Development Lab for manufacturing of Active Pharmaceutical Ingredients which is complimentary and integrated business vertical to existing business of Jeevan Scientific Technology Limited.

Jeevan Scientific Technology Limited
CIN:L72200TG1999PLC031016
Registered Office: Plot No. 1 & 2, Sai Krupa Enclave, Manikonda Jagir, Near Lanco Hills, Golconda Post, Hyderabad-500008.
Statement of standalone Unaudited financial results for the Quarter and Nine Months ended 31st December 2024
(All Amounts in Indian rupees lakhs, except share data and where otherwise stated)

	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31st December 2024	30th September 2024	31st December 2023	31st December 2024	31st December 2023	31 March 2024
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
	Revenue from operations						
	(a) Net sales/Income from operations	1,186.64	1,030.19	1,012.75	3,468.50	2,858.15	3,850.17
I	**Total revenue from operation**	**1,186.64**	**1,030.19**	**1,012.75**	**3,468.50**	**2,858.15**	**3,850.17**
II	Other Income	21.62	16.05	(11.59)	48.82	43.57	69.00
III	**Total income (I+II)**	**1,208.26**	**1,046.24**	**1,001.16**	**3,517.32**	**2,901.72**	**3,919.17**
IV	**Expenses**						
	(a) Cost of materials consumed	80.96	77.09	85.62	252.92	267.07	368.48
	(b) Changes in Inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-	-
	(c) Employee benefits expense	367.59	371.07	369.07	1,103.84	1,126.60	1,517.82
	(d) Finance costs	25.74	27.00	13.11	68.19	57.09	73.28
	(e) Depreciation and Amortization expense	123.2	124.99	134.54	376.03	414.12	554.68
	(f) Other Expenses	534.08	387.55	448.86	1,374.22	1,083.45	1,527.83
	Total Expenses (IV)	**1,131.57**	**987.70**	**1,051.20**	**3,175.19**	**2,948.33**	**4,042.09**
V	**Profit/ (Loss) before Tax (III-IV)**	**76.69**	**58.54**	**(50.04)**	**342.13**	**(46.61)**	**(122.92)**
VI	**Tax Expenses**						
	(a) Current tax	11.96	9.13	(0.53)	53.37	-	-
	(b) MAT Credit / (Entitlement)	(11.96)	(9.13)	-	(53.37)	-	-
	(c) Deferred tax	44.44	43.55	(10.16)	134.84	(15.31)	(17.96)
	Total tax expense	**44.44**	**43.55**	**(10.69)**	**134.84**	**(15.31)**	**(17.96)**
VII	**Profit(Loss) for the period/year (V-VI)**	**32.25**	**14.99**	**(39.35)**	**207.28**	**(31.30)**	**(104.96)**

JEEVAN SCIENTIFIC TECHNOLOGY LTD. HYDERABAD

VIII	**Other Comprehensive Income**						
	A (i) Items that will not be reclassified subsequently to profit or loss	-	(3.83)	-	(3.83)	(2.90)	2.90
	(ii) Income tax relating to items that will not be reclassified subsequently to profit or loss	-	-	-	-	0.81	(0.81)
	B (i) Items that will be reclassified subsequently to profit or loss	-	-	-	-	-	
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	
	Total other comprehensive income/(loss) for the period	-	**(3.83)**	-	**(3.83)**	**(2.09)**	**2.09**
IX	**Total Comprehensive income for the period (VII+VIII)**	**32.25**	**11.16**	**(39.35)**	**203.45**	**(33.39)**	**(102.87)**
X	**Paid Up equity share capital (Face value of Rs.10/- each)**	**1,583.40**	**1,548.02**	**1,548.02**	**1,583.40**	**1,548.02**	**1,548.02**
XI	**Other equity**		-	-	-	-	**3,332.13**
XII	**Earnings per equity share (of Rs. 10/- each) (not annualized for the quarters)**						
	a) Basic	0.21	0.10	(0.25)	1.33	(0.20)	(0.68)
	b) Diluted	0.20	0.10	(0.25)	1.30	(0.20)	(0.68)

Notes to the Unaudited financial results

1. The above Unaudited standalone financial results of the company have been prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under section133 of the Companies Act 2013 with relevant rules issued thereunder, other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India.
2. The above Unaudited standalone results have been reviewed by the Audit Committee at its meeting held on 06th February 2025 of the board and approved by the Board of Directors of the Company at their meeting held on 06th February 2025
3. The Statutory Auditors of the Company have carried out the limited review of the above unaudited financial results and their report has been placed before the board at the said meeting as required under Regulation 33 of SEBI (LODR) Regulations, 2015
4. Employee benefit expenses for the Quarter ending 31st December 2024 includes Rs.19.24 Lakhs towards ESOP Scheme 2016 provided as per " Ind AS 102 - Share Based Payments".
5. The company operates in one reportable business segment i.e. Clinical Research Services. Hence segment reporting as per Ind AS 108 is not applicable.
6. The results for the Quarter and Nine Months ended 31st December 2024 are also available on website of BSE Limited and on the Company's website.
7. Figures for the previous periods have been rearranged/ reclassified wherever necessary to confirm to the current period presentation.

for Jeevan Scientific Technology Limited

K. Krishna Kishore
Vice Chairman & Managing Director
(DIN:00876539)

JEEVAN SCIENTIFIC TECHNOLOGY LTD. HYDERABAD

Place: Hyderabad.
Date:06th February, 2025

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

CIN:L72200TG1999PLC031016

Registered Office: Plot No. 1 & 2, Sai Krupa Enclave, Manikonda Jagir, Near Lanco Hills, Golconda Post, Hyderabad-500008.

Statement of consolidated Unaudited financial results for the Quarter and Nine Months ended 31 December 2024

(All Amounts in Indian rupees lakhs, except share data and where otherwise stated)

	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31st December 2024	30th September 2024	31st December 2023	31st December 2024	31st December 2023	31 March 2024
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
	Revenue from operations						
	(a) Net sales/Income from operations	1,250.72	1,139.82	1,012.75	3,678.57	2,858.15	3,965.04
I	**Total revenue from operation**	1,250.72	1,139.82	1,012.75	3,678.57	2,858.15	3,965.04
II	Other Income	22.78	16.35	(11.40)	50.59	44.19	67.46
III	**Total income (I+II)**	**1,273.50**	**1,156.17**	**1,001.35**	**3,729.17**	**2,902.34**	**4,032.51**
IV	**Expenses**						
	(a) Cost of materials consumed	85.28	80.49	85.62	264.88	267.07	381.70
	(b) Changes in Inventories of finished goods, work-in-progress and stock-in-trade			-	-	-	-
	(c) Employee benefits expense	403.41	404.60	369.41	1,206.72	1,127.53	1,555.85
	(d) Finance costs	43.32	44.97	14.64	121.49	63.90	96.80
	(e) Depreciation and Amortization expense	147.62	149.07	139.50	448.08	429.00	592.93
	(f) Other Expenses	554.71	405.24	456.44	1,427.64	1,099.30	1,565.61
	Total Expenses (IV)	**1,234.34**	**1,084.37**	**1,065.61**	**3,468.81**	**2,986.80**	**4,192.90**
V	**Profit/ (Loss) before tax (III-IV)**	**39.16**	**71.80**	**(64.26)**	**260.36**	**(84.46)**	**(160.39)**
VI	**Tax expenses**						
	(a) Current tax	11.96	9.13	(0.53)	53.37	-	-
	(b) MAT Credit / (Entitlement)	(11.96)	(9.13)	-	(53.37)	-	-
	(c) Deferred tax	34.60	46.83	(15.01)	128.24	(24.98)	(27.67)
VII	**Profit/(Loss) for the period/year**	**4.56**	**24.97**	**(48.72)**	**132.12**	**(59.48)**	**(132.72)**
VIII	**Other Comprehensive Income**						
	A (i) Items that will not be reclassified subsequently to profit or loss	-	(3.83)	-	(3.83)	(2.90)	2.90
	(ii) Income tax relating to items that will not be reclassified subsequently to profit or loss	-	-	-	-	0.81	(0.81)
	B (i) Items that will be reclassified subsequently to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Comprehensive Income for the period /year	-	**(3.83)**	-	**(3.83)**	**(2.09)**	**2.09**
IX	**Total Comprehensive Income for the period /year**	**4.56**	**21.14**	**(48.72)**	**128.29**	**(61.57)**	**(130.62)**
X	**Paid Up Equity Share Capital (Face Value of Rs.10/- each)**	**1,583.40**	**1,548.02**	**1,548.02**	**1,583.40**	**1,548.02**	**1,548.02**
XI	**Other equity excluding revaluation reserve**		-	-		-	**3,294.82**
XII	**Earnings per Equity share**						
	a) Basic (Amount in Rupees)	0.03	0.16	(0.31)	0.85	(0.38)	(0.86)
	b) Diluted (Amount in Rupees)	0.03	0.16	(0.31)	0.83	(0.38)	(0.86)

JEEVAN SCIENTIFIC TECHNOLOGY LTD. HYDERABAD

XIII	**Net profit attributable to:**						
	Owners of the company	10.50	23.86	(47.68)	143.34	(56.35)	(129.64)
	Non-Controlling interest	(5.94)	1.11	(1.04)	(11.22)	(3.13)	(3.08)
XIV	**Other comprehensive income attributable to:**						
	Owners of the company	-	(3.83)	-	(3.83)	(2.09)	2.09
	Non-Controlling interest	-	-	-	-	-	-
XV	**Total comprehensive income attributable to:**						
	Owners of the company	10.50	20.03	(47.68)	139.51	(58.44)	(127.54)
	Non-Controlling interest	(5.94)	1.11	(1.04)	(11.22)	(3.13)	(3.08)

Notes to the Unaudited financial results

1 The above Unaudited Consolidated financial results of the company have been prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under section133 of the Companies Act 2013 with relevant rules issued thereunder, other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India.

2 The above Unaudited Consolidated results have been reviewed by the Audit Committee at its meeting held on 06th December 2024 of the board and approved by the Board of Directors of the Company at their meeting held on 06th December 2024

3 The Statutory Auditors of the Company have carried out the limited review of the above unaudited financial results and their report has been placed before the board at the said meeting as required under Regulation 33 of SEBI (LODR) Regulations, 2015

4 Employee benefit expenses for the Quarter ending 30th September 2024 includes Rs.19.24 Lakhs towards ESOP Scheme 2016 provided as per " Ind AS 102 - Share Based Payments".

5 The company operates in one reportable business segment i.e. Clinical Research Services. Hence segmental reporting as per Ind AS 108 is not applicable.

6 The results for the Quarter and Nine Months ended 31st December 2024 are also available on website of BSE Limited and on the Company's website.

7 Figures for the previous periods have been rearranged/ reclassified wherever necessary to confirm to the current period presentation.

for Jeevan Scientific Technology Limited

K. Krishna Kishore
Vice Chairman & Managing Director
(DIN:00876539)

JEEVAN SCIENTIFIC TECHNOLOGY LTD. HYDERABAD

Place: Hyderabad.
Date:06th February, 2025

PAVULURI & Co.
CHARTERED ACCOUNTANTS
Plot No.48, Flat No.301,
Sucasa, Phase - I, Kavuri Hills,
Hyderabad - 500 033.
Ph : 040-2970 2638 / 2639 / 2640
Email : pavuluriandco@gmail.com

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF
JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **JEEVAN SCIENTIFIC TECHNOLOGY LIMITED** ("the Parent Company"), for the quarter ended December 31, 2024 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For PAVULURI & Co
Chartered Accountants
Firm Reg. No: 012194S

N. Rajesh

PAVULURI & CO. Firm Reg. No. 012194S HYDERABAD Chartered Accountants

CA N RAJESH
Partner
M. No: 223169

Place : Hyderabad
Date :06/02/2025

UDIN # 25223169BMILKY7143

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED
CIN:L72200TG1999PLC031016
Registered Office: Plot No. 1 & 2, Sai Krupa Enclave, Manikonda Jagir, Near Lanco Hills, Golconda Post, Hyderabad-500008.
Statement of consolidated Unaudited financial results for the Quarter and Nine Months ended 31 December 2024
(All Amounts in Indian rupees lakhs, except share data and where otherwise stated)

	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31st December 2024	30th September 2024	31st December 2023	31st December 2024	31st December 2023	31 March 2024
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
	Revenue from operations						
	(a) Net sales/Income from operations	1,250.72	1,139.82	1,012.75	3,678.57	2,858.15	3,965.04
I	**Total revenue from operation**	**1,250.72**	**1,139.82**	**1,012.75**	**3,678.57**	**2,858.15**	**3,965.04**
II	Other Income	22.78	16.35	(11.40)	50.59	44.19	67.46
III	**Total income (I+II)**	**1,273.50**	**1,156.17**	**1,001.35**	**3,729.17**	**2,902.34**	**4,032.51**
IV	**Expenses**						
	(a) Cost of materials consumed	85.28	80.49	85.62	264.88	267.07	381.70
	(b) Changes in Inventories of finished goods, work-in-progress and stock-in-trade			-	-	-	-
	(c) Employee benefits expense	403.41	404.60	369.41	1,206.72	1,127.53	1,555.85
	(d) Finance costs	43.32	44.97	14.64	121.49	63.90	96.80
	(e) Depreciation and Amortization expense	147.62	149.07	139.50	448.08	429.00	592.93
	(f) Other Expenses	554.71	405.24	456.44	1,427.64	1,099.30	1,565.61
	Total Expenses (IV)	**1,234.34**	**1,084.37**	**1,065.61**	**3,468.81**	**2,986.80**	**4,192.90**
V	**Profit/ (Loss) before tax (III-IV)**	**39.16**	**71.80**	**(64.26)**	**260.36**	**(84.46)**	**(160.39)**
VI	**Tax expenses**						
	(a) Current tax	11.96	9.13	(0.53)	53.37	-	-
	(b) MAT Credit / (Entitlement)	(11.96)	(9.13)	-	(53.37)	-	-
	(c) Deferred tax	34.60	46.83	(15.01)	128.24	(24.98)	(27.67)
VII	**Profit/(Loss) for the period/year**	**4.56**	**24.97**	**(48.72)**	**132.12**	**(59.48)**	**(132.72)**
VIII	**Other Comprehensive Income**						
	A (i) Items that will not be reclassified subsequently to profit or loss	-	(3.83)	-	(3.83)	(2.90)	2.90
	(ii) Income tax relating to items that will not be reclassified subsequently to profit or loss	-	-	-	-	0.81	(0.81)
	B (i) Items that will be reclassified subsequently to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Comprehensive Income for the period /year	-	**(3.83)**	-	**(3.83)**	**(2.09)**	**2.09**
IX	**Total Comprehensive Income for the period /year**	**4.56**	**21.14**	**(48.72)**	**128.29**	**(61.57)**	**(130.62)**
X	**Paid Up Equity Share Capital (Face Value of Rs.10/- each)**	**1,583.40**	**1,548.02**	**1,548.02**	**1,583.40**	**1,548.02**	**1,548.02**
XI	**Other equity excluding revaluation reserve**		-	-		-	**3,294.82**
XII	**Earnings per Equity share**						
	a) Basic (Amount in Rupees)	0.03	0.16	(0.31)	0.85	(0.38)	(0.86)
	b) Diluted (Amount in Rupees)	0.03	0.16	(0.31)	0.83	(0.38)	(0.86)

JEEVAN SCIENTIFIC TECHNOLOGY LTD. HYDERABAD

XIII	**Net profit attributable to:**						
	Owners of the company	10.50	23.86	(47.68)	143.34	(56.35)	(129.64)
	Non-Controlling interest	(5.94)	1.11	(1.04)	(11.22)	(3.13)	(3.08)
XIV	**Other comprehensive income attributable to:**						
	Owners of the company	-	(3.83)	-	(3.83)	(2.09)	2.09
	Non-Controlling interest	-	-	-	-	-	-
XV	**Total comprehensive income attributable to:**						
	Owners of the company	10.50	20.03	(47.68)	139.51	(58.44)	(127.54)
	Non-Controlling interest	(5.94)	1.11	(1.04)	(11.22)	(3.13)	(3.08)

Notes to the Unaudited financial results

1. The above Unaudited Consolidated financial results of the company have been prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under section133 of the Companies Act 2013 with relevant rules issued thereunder, other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India.
2. The above Unaudited Consolidated results have been reviewed by the Audit Committee at its meeting held on 06th February, 2025 of the board and approved by the Board of Directors of the Company at their meeting held on 06th February, 2025
3. The Statutory Auditors of the Company have carried out the limited review of the above unaudited financial results and their report has been placed before the board at the said meeting as required under Regulation 33 of SEBI (LODR) Regulations, 2015
4. Employee benefit expenses for the Quarter ending 31st December 2024 includes Rs.19.24 Lakhs towards ESOP Scheme 2016 provided as per " Ind AS 102 - Share Based Payments".
5. The company operates in one reportable business segment i.e. Clinical Research Services. Hence segmental reporting as per Ind AS 108 is not applicable.
6. The results for the Quarter and Nine Months ended 31st December 2024 are also available on website of BSE Limited and on the Company's website.
7. Figures for the previous periods have been rearranged/ reclassified wherever necessary to confirm to the current period presentation.

for Jeevan Scientific Technology Limited

K. Krishna Kishore
Vice Chairman & Managing Director
(DIN:00876539)

JEEVAN SCIENTIFIC TECHNOLOGY LTD. HYDERABAD

Place: Hyderabad.
Date:06th February, 2025